IP Library › Granted Patent US 12,428,424
Granted Patent B2
US 12,428,424 · App. 17/629,041 · Granted Sep 30, 2025

Estrogen receptor-modulating compounds

Inventor: Chris P. Miller (San Mateo, CA)
Assignee: RADIUS PHARMACEUTICALS, INC.
C07D487/04A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,424
App. No.
17/629,041
Granted
Sep 30, 2025
Kind
B2
Abstract

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Claims (17)

1. A compound having a structure selected form the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having a structure according to Formula D-105:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , having a structure according to Formula D-106:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , having a structure according to Formula D-107:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , having a structure according to Formula D-108:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , having a structure according to Formula D-109:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , having a structure according to Formula D-110:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

9. A method of treating a disease, syndrome, illness, or symptom associated with insufficient or overabundant estrogen levels in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. A method of treating a cancer selected from the group consisting of prostate cancer, breast cancer, endometrial cancer, lung cancer, hepatocellular cancer, lymphoma, multiple endocrine neoplasia, vaginal cancer, renal cancer, thyroid cancer, testicular cancer, leukemia, and ovarian cancer in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 30, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: RADIUS HEALTH, INC.
Reel/Frame 073278/0396 →
SECURITY INTEREST Recorded Aug 16, 2022
From: RADIUS HEALTH, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061179/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2022
From: MILLER, CHRIS P.
To: RADIUS PHARMACEUTICALS, INC.
Reel/Frame 059582/0481 →
Continuity (2)
Provisional Application 62876963 · Jul 22, 2019
Related Publication 20220281875A1 · Sep 8, 2022
References Cited (26)
US 5916916A · Hauser · 1999 [cited by applicant]
US 6358943B1 · Ullrich · 2002 [cited by examiner]
US 6821989B2 · Rosati · 2004 [cited by applicant]
US 6844336B2 · Kuenzer et al. · 2005 [cited by applicant]
US 7138426B2 · DiNinno · 2006 [cited by applicant]
US 9187460B2 · Smith · 2015 [cited by applicant]
US 11384068B2 · Miller · 2022 [cited by examiner]
US 20030130276A1 · Rosati · 2003 [cited by applicant]
EA 000815B1 · 2000 [cited by applicant]
GB 2300857A · 1996 [cited by examiner]
WO 9907377A1 · 1999 [cited by applicant]
WO 9915500A1 · 1999 [cited by applicant]
WO 2004032716A2 · 2004 [cited by applicant]
WO 2016097072A1 · 2016 [cited by applicant]
WO 2016189011A1 · 2016 [cited by applicant]
WO 2019144132A1 · 2019 [cited by applicant]
Paterni, I. et al. Expert Opinion on Therapeutic Patents, 2013, 23(10), 1247-1271 (Year: 2013). [cited by examiner]
PCT/US2020/042903 International Search Report dated Sep. 15, 2020. [cited by applicant]
Denya, Ireen, et al, Indazole derivatives and their therapeutic applications: a patent review (2013-2017), Expert Opinion on Therapeutic Patents, vol. 28, No. 6 May 11, 2018, pp. 441-453, XP055726835, ISSN: 1354-3776. [cited by applicant]
China 202080051792.9 Search Report dated Aug. 1, 2023. [cited by applicant]
Russia 2022101182 Search Report dated Dec. 21, 2023. [cited by applicant]
Singapore 11202200582W Written Opinion and Search Report date Sep. 6, 2023. [cited by applicant]
Belikov, V.G., Pharmaceutical Chemistry, Moscow, High School, vol. 1, pp. 43-47, 1993. [cited by applicant]
Durnov, L.A., et al., Pediatric Oncology, Second Edition, 2002. [cited by applicant]
Dyson, G., et al., Chemistry of Synthetic Drugs, Publishing House, MIR, Moscow, 1964. [cited by applicant]
Kummerer, K., Pharmaceuticals in the Environment, The Annual Review of Environment and Resources, vol. 35, pp. 57-75, Aug. 18, 2010. [cited by applicant]